Menicon saw no growth in patent filings and highest growth of 1.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 1.99%. GlobalData’s DataBook provides a comprehensive analysis of Menicon‘s patent filings and grants. Buy the databook here.
Menicon has been focused on protecting inventions in European Patent Office(EPO) with five publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 100% filings and 57% grants. The European Patent Office(EPO), and United States(US) patent Office are among the top ten patent offices where Menicon is filings its patents. Among the top granted patent authorities, Menicon has 57% of its grants in European Patent Office(EPO) and 43% in United States(US).
Johnson & Johnson could be the strongest competitor for Menicon
In terms of grant share, Menicon stands in eighth position among its competitors. Johnson & Johnson and Menicon secured the top positions according to recent patent publication data.
Patents related to 3d printing lead Menicon's portfolio
Menicon has the highest number of patents in 3d printing. For 3d printing no patents were filed and 100% of patents were granted in Q2 2024.
Ophthalmic devices related patents lead Menicon portfolio followed by contact lenses
Menicon has highest number of patents in ophthalmic devices followed by contact lenses.
For comprehensive analysis of Menicon's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.